Related Experiment Video
Updated: Mar 18, 2026
09:12
Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
Published on: March 17, 2019
10.3K
Risk-taking behavior and impulsivity among HCV-infected patients
Adriana Dantas-Duarte1, Mychelle Morais-de-Jesus1, Ana Paula Nunes1
1Programa de Pós-graduação em Medicina e Saúde, Faculdade de Medicina da Universidade Federal da Bahia, Salvador, Bahia, Brazil.
Psychiatry Research
|July 3, 2016
Summary
Hepatitis C virus (HCV) patients exhibit higher impulsivity, a trait linked to risk behaviors. This impulsivity significantly mediates at-risk behavior in individuals with HCV.
Area of Science:
- Hepatology
- Psychiatry
- Behavioral Science
Background:
- Hepatitis C virus (HCV) infection is linked to risk behaviors.
- Impulsivity is a known predictor of risk behaviors.
- The relationship between HCV, impulsivity, and risk behaviors requires further investigation.
Purpose of the Study:
- To investigate impulsivity levels in patients with HCV compared to those with non-viral liver diseases.
- To determine if impulsivity mediates risk behaviors in HCV-infected individuals.
Main Methods:
- Adult liver disease patients (n=269) were grouped into viral (HCV, n=157) and non-viral (n=112) cohorts.
- Risk behaviors assessed via sociodemographic questionnaire.
- Impulsivity measured using the Barratt Impulsiveness Scale (BIS-11).
- Psychiatric comorbidities evaluated with the Mini International Neuropsychiatric Interview (MINI 5.0.0).
Main Results:
- HCV patients demonstrated significantly higher impulsivity across all domains (attentional, motor, nonplanning) compared to the non-viral group.
- Higher impulsivity levels were associated with increased risk behaviors.
- Impulsivity was found to significantly mediate at-risk behavior in the HCV group, independent of psychiatric comorbidities.
Conclusions:
- HCV infection is associated with heightened impulsivity, even after controlling for mental health conditions.
- Impulsivity plays a crucial role in mediating risk behaviors among individuals with HCV.
- Understanding this link may inform targeted interventions for HCV prevention and management.
Related Concept Videos
01:25Hepatitis
6
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
324
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
324
01:24Drug Toxicity: Risk factors
113
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
113
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
327
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
01:16Hepatic Drug Excretion: Influencing Factors
708
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
708